Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Target
3.2. Snippet by Indication
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Incidence of Chronic Inflammatory Conditions
4.1.1.2. Rising Product Approvals and Market Access
4.1.2. Restraints
4.1.2.1. High Cost of Interleukin Inhibitors
4.1.2.2. XX
4.1.3. Opportunities
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Epidemiology
5.3. Pricing Analysis
5.4. Pipeline Analysis
5.5. Patent Analysis
5.6. Regulatory Analysis
6. By Target
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target
6.1.2. Market Attractiveness Index, By Target
6.2. Interleukin-1*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Interleukin-2
6.4. Interleukin-6
6.5. Interleukin-12
6.6. Interleukin-17
6.7. Interleukin-23
6.8. Others
7. By Indication
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
7.1.2. Market Attractiveness Index, By Indication
7.2. Psoriasis*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Atopic Dermatitis
7.2.4. Arthritis
7.2.5. Asthma
7.2.6. Inflammatory Bowel Disease (IBD)
7.2.7. Others
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Target
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
Key Market Players
11.1. Sanofi*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue’s
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals etc.
11.1.5. SWOT Analysis
11.2. Regeneron Pharmaceuticals, Inc.
11.3. Novartis AG
11.4. Eli Lilly and Company
11.5. GSK plc.
11.6. Johnson & Johnson Services, Inc.
11.7. AstraZeneca.
11.8. AbbVie.
11.9. F. Hoffmann-La Roche Ltd
11.10. Sun Pharmaceutical Industries, Inc.
11.11. Ortho Dermatologics’ affiliated entities.
11.12. Sobi, Inc.
11.13. UCB, Inc.
11.14. Teva Pharmaceutical Industries Ltd.
11.15. LEO Pharma Inc.
11.16. Kiniksa Pharmaceuticals.
11.17. Boehringer Ingelheim International GmbH.
11.18. Galderma Laboratories, L.P.
* Similar data will be provided for each market player.
Emerging Market Players
11.19. AnaptysBio, Inc.
11.19.1. Pipeline Products Description
11.19.2. Product Key Performance Indicators (KPIs)
11.19.3. Key Activities
11.19.4. Market Entry Timelines
11.19.5. Product Penetration Rate
11.19.6. Sales Estimation and Projections
11.20. Huabo Biopharm (Shanghai) Co., Ltd.
11.21. CSL
11.22. DICE Therapeutics
* Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us